2022
DOI: 10.3390/ijms23052857
|View full text |Cite
|
Sign up to set email alerts
|

Novel Design of Neuropeptide-Based Drugs with β-Sheet Breaking Potential in Amyloid-Beta Cascade: Molecular and Structural Deciphers

Abstract: Our work discusses the investigation of 75 peptide-based drugs with the potential ability to break the β-sheet structures of amyloid-beta peptides from senile plaques. Hence, this study offers a unique insight into the design of neuropeptide-based drugs with β-sheet breaker potential in the amyloid-beta cascade for Alzheimer’s disease (AD). We started with five peptides (15QKLVFF20, 16KLVFF20, 17LVFF20, 16KLVF19 and 15QKLV18), to which 14 different organic acids were attached at the N-terminal. It was necessar… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 70 publications
0
0
0
Order By: Relevance
“…However, due to their low intrinsic toxicity, peptide-based drugs may be a viable option for treating the symptoms of a variety of AD diseases. Neurological conditions such as stroke, pain, brain tumors, psychiatric disorders, and neurodegeneration are treated with effective and precise peptidebased drugs [14]. Many methods have been developed to identify neuropeptides.…”
Section: Introductionmentioning
confidence: 99%
“…However, due to their low intrinsic toxicity, peptide-based drugs may be a viable option for treating the symptoms of a variety of AD diseases. Neurological conditions such as stroke, pain, brain tumors, psychiatric disorders, and neurodegeneration are treated with effective and precise peptidebased drugs [14]. Many methods have been developed to identify neuropeptides.…”
Section: Introductionmentioning
confidence: 99%